The AAIC has gained news coverage from ABC, the BBC, CBS, CNN, NBC, the Associated Press, Reuters," Good Morning America"," The Wall Street Journal", "The Washington Post", "USA Today", WebMD.com and Forbes.com. Through the customs of the Alzheimer's Association International Conference on Alzheimer's Disease (ICAD), the AAIC attempts to gather authority figures from more than 70 different countries to network and converse the most current dementia research outcomes and ideas in 2018. Established in 2010, the Alzheimer's Impact Movement (AIM) is a registered 501(c)(4) advocacy organization that works in partnership with the Alzheimer's Association. AIM is a membership organization that is non-partisan, non-profit, and their objective is to make Alzheimer's disease a national importance. AIM supports policies designed to find an end to Alzheimer's disease through improved investments in research, enhanced care and support, and the advancement of methods designed to decrease the chance of developing dementia. AIM and the Alzheimer's Association offers a 24/7 helpline to provide advice, information, and support for those living with Alzheimer's disease, their caretakers, medical experts, and the community. AIM is a sister organization of the Alzheimer's Association, which has a voluntary and non-partisan political action committee, AIMPAC. AIMPAC is the political side of AIM, their goal is to inform members of Congress about the serious problems of Alzheimer's disease with the help of the main concerns of the Alzheimer's Association. During the 2015 and 2016 United States Presidential primary season, AIM supporters pressured each of the candidates for their individual ideas to end Alzheimer's. In the 2016 Presidential Election, AIM and the Alzheimer's Association distributed a national voter survey and results showed that 73 million voters in America knew someone close to them with Alzheimer's disease. The Alzheimer's Association has partaken in many opportunities to assist in diagnosing and treating Alzheimer's Disease. In 1987 the Alzheimer's Association teamed up with the NIA and Warner-Lambert Pharmaceutical Company (now known as Pfizer) and helped launch and recruit participants for clinical trials of the first drug to specifically target symptoms of Alzheimer's Disease. In 1995, the Alzheimer's Association funded the development of a mouse model of a rare neurodegenerative disorder, thus laying down the technical foundation for Alzheimer's mouse models. In 2003, the Alzheimer's Association partnered with the NIA in finding participants for the National Alzheimer's Disease Genetics Study in order to identify Alzheimer's risk in genes.